Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Megan C Herink"'
Autor:
Megan C. Herink, Andrew Seaman, Gillian Leichtling, Jessica E. Larsen, Tonhi Gailey, Ryan Cook, Ann Thomas, P. Todd Korthuis
Publikováno v:
Addiction Science & Clinical Practice, Vol 18, Iss 1, Pp 1-11 (2023)
Abstract Background Hepatitis C virus (HCV) transmission is primarily driven by injection drug use, and acute HCV infection rates are increased in rural communities with substantial barriers to care. Treatment of HCV in persons who use drugs (PWUD) i
Externí odkaz:
https://doaj.org/article/1e53ba4e22694696aa2908208a445a56
Autor:
Richie Kohli, Karan Replogle, Andrea Gough-Goldman, Barry Taylor, Brandon Maughan, Harjit Singh Sehgal, Megan C. Herink, Rosemarie Hemmings, Sean Mahoney, Margaret McLain McDonnell, Kenneth McLemore, Eli Schwarz
Publikováno v:
BMC Oral Health, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Uninformed opioid prescribing by dentists has contributed to the current opioid crisis. This report describes the development and implementation of an innovative, interactive, multidisciplinary, and participant-centric telementori
Externí odkaz:
https://doaj.org/article/d9a16a407fa64306a491c890058cdb7d
Publikováno v:
Pharmacy, Vol 10, Iss 5, p 126 (2022)
The “breakthrough therapy” designation (BTD) is a recent mechanism implemented by the United States Food and Drug Administration (FDA) to expedite access to drugs that address unmet needs. The purpose of this study is to describe pharmacists’ k
Externí odkaz:
https://doaj.org/article/b2abf1533abf41538e51420033718df7
Autor:
Rachel W. Flurie, Jennifer Austin Szwak, Tina Beck, Megan C. Herink, Katie Wdowiarz, Lisa Hong, Thaddaus Hellwig, Branden Nemecek, Emmeline Tran, Rima A. Mohammad
Publikováno v:
JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 6:103-110
Autor:
Rebekah R Bartholomew, Brie N Noble, Jennifer J Stanislaw, Megan Viehmann, Megan C Herink, Jon P Furuno
Publikováno v:
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
Purpose Direct oral anticoagulant (DOAC) medications have improved safety, efficacy, and laboratory monitoring requirements compared to warfarin. However, available data are limited on the frequency and clinical outcomes of pharmacist-driven warfarin
Publikováno v:
Journal of Pharmacy Practice. :089719002311651
Background Treatment with medications for opioid use disorder (MOUD) may improve hepatitis C virus (HCV) treatment outcomes by providing additional contact with health care professionals to support patient engagement. Objective: We describe a pharmac
Autor:
Jay L. Martello, Winter J. Smith, Lisa M. Avery, Elizabeth Rogers, Janet P. Engle, Megan C. Herink, Christy S. Harris, Sara Jane E. Faro, Katherine G. Moore, Emily J. Ashjian, Paul M. Stranges, Barkha Jain, Eric J. MacLaughlin, Jill S. Borchert, John M. Burke
Publikováno v:
JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 3:124-132
Publikováno v:
Journal of managed carespecialty pharmacy. 27(7)
BACKGROUND: Although direct-acting antivirals (DAA) have revolutionized the treatment of chronic hepatitis C virus (HCV), many state Medicaid programs have limited coverage because of their expense. In 2015, the Centers for Medicare & Medicaid Servic
Publikováno v:
Drugs. 79:1625-1634
Compared with warfarin, the direct-acting oral anticoagulants (DOAC) have fewer pharmacokinetic drug interactions. However, significant drug interactions do exist with documented changes in DOAC concentrations, which can exceed 100%. Unlike warfarin,
Publikováno v:
Pharmacotherapy. 38(9)
The United States Food and Drug Administration (FDA) has created approval pathways and designations to accelerate access to medications indicated for serious or life-threatening conditions with limited treatment options. Implemented in 2012, the most